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Abstract
S100A8 and S100A9, two Ca2+-binding proteins of the S100
family, are secreted as a heterodimeric complex (S100A8/A9)
from neutrophils and monocytes/macrophages. Serum and
synovial fluid levels of S100A8, S100A9, and S100A8/A9 were
all higher in patients with rheumatoid arthritis (RA) than in
patients with osteoarthritis (OA), with the S100A8/A9
heterodimer being prevalent. By two-color immunofluorescence
labeling, S100A8/A9 antigens were found to be expressed
mainly by infiltrating CD68+ macrophages in RA synovial tissue
(ST). Isolated ST cells from patients with RA spontaneously
released larger amounts of S100A8/A9 protein than did the
cells from patients with OA. S100A8/A9 complexes, as well as
S100A9 homodimers, stimulated the production of
proinflammatory cytokines, such as tumor necrosis factor alpha,
by purified monocytes and in vitro-differentiated macrophages.
S100A8/A9-mediated cytokine production was suppressed
significantly by p38 mitogen-activated protein kinase (MAPK)
inhibitors and almost completely by nuclear factor kappa B (NF-
κB) inhibitors. NF-κB activation was induced in S100A8/A9-
stimulated monocytes, but this activity was not inhibited by p38
MAPK inhibitors. These results indicate that the S100A8/A9
heterodimer, secreted extracellularly from activated tissue
macrophages, may amplify proinflammatory cytokine responses
through activation of NF-κB and p38 MAPK pathways in RA.
Introduction
S100A8 and S100A9 are two members of the S100 protein
family that are characterized by the presence of two Ca2+-
binding sites of the EF-hand type. These proteins are also des-
ignated as migration inhibitory factor- or myeloid-related pro-
tein-8 (MRP8) and MRP14, or calgranulin A and B,
respectively [1-3]. Most members of the S100 family exist in
the form of homodimers or heterodimers within cells and inter-
act with several effector proteins mostly in a Ca2+-dependent
manner, thereby regulating enzyme activities, the dynamics of
cytoskeleton constituents, cell growth and differentiation, and
Ca2+ homeostasis [1]. S100A8 and S100A9 are predomi-
nantly expressed in cells of the myelomonocytic lineage; both
proteins are present at high concentrations in the cytoplasm of
AA = arachidonic acid; CBA = cytometric beads array; CRP = C-reactive protein; ELISA = enzyme-linked immunosorbent assay; EMSA = electro-
phoretic mobility shift assay; esRAGE = endogenous secretory receptor for advanced glycation endproducts; FCS = fetal calf serum; FITC = fluo-
rescein isothiocyanate; GM-CSF = granulocyte-macrophage colony-stimulating factor; ICAM-1 = intracellular adhesion molecule-1; IFN-γ = interferon 
gamma; Ig = immunoglobulin; IL = interleukin; JRA = juvenile rheumatoid arthritis; LPS = lipopolysaccharide; mAb = monoclonal antibody; MAPK = 
mitogen-activated protein kinase; MRP = myeloid-related protein, NF-κB = nuclear factor kappa B; OA = osteoarthritis; PB = peripheral blood; PBMC 
= peripheral blood mononuclear cell; PDTC = 1-pyrrolidinecarbodithioic acid; PE = phycoerythrin; RA = rheumatoid arthritis; RAGE = receptor for 
advanced glycation endproducts; SD = standard deviation; SF = synovial fluid; ST = synovial tissue; TNF-α = tumor necrosis factor alpha; TPCK = 
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neutrophils and monocytes, and the S100A8/A9 heterodimer
is translocated to membrane and cytoskeletal structures upon
activation [4-6]. Intracellular S100A8/A9 complexes play an
important role in myeloid cell maturation, cell trafficking, and
arachidonic acid (AA) metabolism [2].
S100A8 and S100A9 are secreted as complexes from neu-
trophils and monocytes after activation of protein kinase C in
a novel pathway requiring an intact microtubule network [7].
High levels of the proteins have been found in the extracellular
milieu during inflammatory conditions such as rheumatoid
arthritis (RA) [2,3]. The S100A8/A9 heterodimer, originally
identified as an antimicrobial protein, exhibits cytokine-like
functions in the local environment, most notably enhancing
leukocyte recruitment to inflammatory sites and AA transporta-
tion to its target cells [8-10]. However, the nature of surface
receptors for S100A8/A9 and its signaling pathways has not
yet been fully elucidated. The soluble S100A8/A9 complex
binds to the cell surface of endothelial cells by interacting with
specific binding sites such as heparin sulfate proteoglycans
and novel carboxylated glycans [11,12]. In addition, CD36
and the receptor for advanced glycation endproducts (RAGE)
are two other putative receptors for this complex. Interaction
of exogeneous S100A8/A9 and AA complexes with the scav-
enger receptor CD36 facilitates AA uptake by endothelial cells
[13]. RAGE, a scavenger receptor belonging to the immu-
noglobulin (Ig) family that signals to the nuclear factor kappa B
(NF-κB) pathway, was identified as a functional receptor for
the S100A12 protein [14]. Structural similarities between
S100A12 and other S100 proteins [3] and the binding of
S100B and S100A12 to RAGE [1] suggest that RAGE may
be a general receptor for the S100 family of proteins.
The inflamed synovial membrane in patients with RA is charac-
terized by infiltration of inflammatory cells, primarily lym-
phocytes, and macrophages and proliferation of synovial
fibroblasts, together with increased vascularity. Macrophages
play a critical role in the perpetuation of synovial inflammation
and joint destruction mainly by secreting proinflammatory
cytokines such as tumor necrosis factor alpha (TNF-α) and
interleukin 1 (IL-1) [15]. These two cytokines, produced at
high levels by macrophages localized in the lining layer and at
the pannus lesion, induce the synthesis of numerous inflamma-
tory mediators and matrix-degrading enzymes via the activa-
tion of the transcription factor NF-κB and the mitogen-
activated protein kinase (MAPK) cascade [15,16].
Many effector molecules are thought to be involved in the TNF-
α- and IL-1-driven cascade of proinflammatory events in RA.
Concentrations of the S100A8/A9 heterodimer in peripheral
blood (PB) in patients with RA have been increased in associ-
ation with the severity of arthritis [17,18]. More importantly, the
protein was more enriched in synovial fluid (SF) than in blood
circulation [18], and it was expressed in synovial tissue (ST)
macrophages localized in the lining layer adjacent to the carti-
lage-pannus junction [18,19]. These findings suggest an
active role of S100A8/A9 protein in the progressive synovial
inflammation, but their functions relevant to RA pathogenesis
remain to be determined. In the present study, we confirmed
the abundance of S100A8/A9 complexes in the joints of
patients with RA and investigated the effects of recombinant
S100A8/A9 proteins on monocyte/macrophage cytokine pro-
duction and activation of NF-κB and MAPK signaling.
Materials and methods
Patients and samples
Study patients with RA and control patients with osteoarthritis
(OA) were diagnosed according to the revised 1987 criteria of
the American College of Rheumatology (formerly, the Ameri-
can Rheumatism Association) [20,21]. All patients with RA
were receiving prednisolone at no more than 5 mg/day and
various disease-modifying antirheumatic drugs. Paired serum
and SF samples were obtained from 17 patients with RA (14
women, 3 men; mean ± standard deviation (SD) age, 63 ± 9
years) and 17 patients with OA (12 women, 5 men; 65 ± 6
years); SF samples were aspirated from the knee joint during
therapeutic arthrocentesis. Most patients with RA were active;
they had multiple joint tenderness and swelling, systemic
inflammatory responses (mean ± SD, serum C-reactive protein
[CRP, 53 ± 53 mg/liter] and erythrocyte sedimentation ratio
[63 ± 42 mm/hour]), and elevated serum IgM class rheuma-
toid factor titer (110 ± 133 units/ml), whereas patients with
OA did not show evidence of a systemic inflammatory
response. ST samples were obtained from patients with RA
and patients with OA at the time of total knee joint replace-
ment. PB samples were collected from healthy volunteers. All
patients and healthy individuals gave informed consent.
Isolation and culture of ST cells
Fresh ST samples were fragmented and digested with colla-
genase and DNase in RPMI 1640 medium (Life Technologies,
Gaithersburg, MD, USA) for 1 hour at 37°C. After removal of
tissue debris, cells were washed with medium. The resultant
single-cell suspensions were adjusted at a density of 1 × 106
cells per ml in culture medium (RPMI 1640 medium supple-
mented with 25 mM HEPES, 2 mM L-glutamine, 2% nones-
sential amino acids, 100 IU/ml penicillin, and 100 µg/ml
streptomycin; Life Technologies) with 10% heat-inactivated
fetal calf serum (FCS; Life Technologies). The cells were incu-
bated in the wells of six-well plates (Corning, Corning, NY,
USA) at 37°C in a humidified atmosphere containing 5% CO2.
Culture supernatants were harvested 72 hours later and
stored at -30°C until the S100A8/A9 assay.
Immunoassay for S100 proteins and cytokines
Concentrations of S100A8, S100A9, and S100A8/A9 were
measured in duplicate by the quantitative sandwich enzyme-
linked immunosorbent assay (ELISA) using commercially avail-
able kits (BMA Biomedicals AG, Augst, Switzerland) accord-
ing to the manufacturer's instructions. The detection limits forAvailable online http://arthritis-research.com/content/8/3/R69
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S100A8, S100A9, and S100A8/9 were 0.69, 0.31, and 4.69
ng/ml, respectively.
Concentrations of TNF-α, IL-1-β, IL-6, IL-8, IL-10, and IL-12
p70 in monocyte culture supernatants were measured by cyto-
metric beads array (CBA) with a series of anticytokine mono-
clonal antibody (mAb)-coated beads and phycoerythrin-
conjugated anticytokine mAbs followed by flow cytometric
analysis performed on a FACScan flow cytometer using the
CBA kit and CBA software (all three obtained from Becton,
Dickinson and Company, San Jose, CA, USA). TNF-α concen-
trations in some experiments were measured using the ELISA
kits (Becton, Dickinson and Company). The detection limits for
cytokines were 20 pg/ml.
Two-color immunofluorescence labeling
Cryostat sections (4 µm) from ST samples were fixed in ace-
tone and blocked with 10% donkey serum for 30 minutes.
Double immunofluorescence was performed by serially incu-
bating sections with 1 µg/ml of mouse IgG1 mAb against
human S100A8 (8-5C2), S100A9 (S36.48), or S100A8/A9
(27E10, which exclusively recognizes the heterodimer but not
the homodimers [22]; BMA Biomedicals AG) or isotype-
matched control mAb (BMA Biomedicals AG) at 4°C over
night, followed by incubation with rhodamine-conjugated don-
key anti-mouse IgG1 mAb (Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA) for 30 minutes at room
temperature, and subsequently with 1 µg/ml of fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD68 mAb (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or control mAb (Santa
Cruz Biotechnology) for 30 minutes at room temperature. The
double immunofluorescence of sections was examined with an
LSM510 inverted laser-scanning confocal microscope (Carl
Zeiss, Jena, Germany) and illuminated with 488 and 568 nm
of light. Images decorated with FITC and rhodamine were
recorded simultaneously through separate optical detectors
with a 530-nm band-pass filter and a 590-nm long-pass filter,
respectively. Pairs of images were superimposed for colocali-
zation analysis.
Preparation of S100 proteins
Recombinant human S100A8 and S100A9 proteins were pre-
pared as described previously [23,24]. Briefly, competent
Escherichia coli strain BL21 (DE3) cells (Novagen, Madison,
WI, USA) were transformed with the pET1120-MRP8wt and
pET1120 S100A9wt vectors. The transformed cells were
grown at 37°C in (2× YT) media supplemented with 100 µg/
ml ampicillin for 24 hours; the cells produced the proteins as
inclusion bodies. The harvested cells were solubilized with B-
PER™ Bacterial Protein Extraction Reagent (Pierce, Rockford,
IL, USA). The inclusion bodies were solubilized with Inclusion
Body Solubilization Reagent (Pierce), and the proteins were
refolded according to the manufacturer's protocol. The pro-
teins were purified by reverse-phase column chromatography
(Resource™ RPC; Amersham Bioscience, Buckingamshire,
UK) furnished in a BioLogic HR system (Bio-Rad, Hercules,
CA, USA), followed by UNO-Q anion exchange chromatogra-
phy (Bio-Rad). The buffer systems used were the same as
those described previously [23]. The purity of the S100A8
protein was found to be greater than 95% by SDS-PAGE
(sodium dodecyl sulfate-polyacrylamide gel electophoresis)
and silver-staining, followed by densitometric analysis using
the ImageJ program (Sun Microsystems, Santa Clara, CA,
USA). Because the S100A9 showed weak silver-staining, its
purity was estimated by Coomasie Brilliant Blue staining and
densitometric analysis to be greater than 95%. The endotoxin
content was measured using an endotoxin-specific assay kit
(Endospecy; Seikagaku Kogyo, Tokyo, Japan), and the 10 µM
solutions of recombinant S100A8 and S100A9 used in the
present study contained endotoxin at 0.255 and 0.467 ng/ml,
respectively. The mixture of equal amounts of S100A8 and
S100A9 solutions was found by its specific ELISA to mostly
form the heterodimer.
Stimulation of monocytes and in vitro-differentiated 
macrophages with S100 proteins
PB mononuclear cells (PBMCs) were prepared from
heparinized PB samples of healthy individuals by Ficoll-
Hypaque density gradient centrifugation. Monocytes were
purified from PBMCs by negative selection using monocyte
isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer's instructions. The monocyte
suspensions were adjusted at a density of 1 × 106 cells per ml
in culture medium with 10% FCS and were incubated in the
wells of 48-well plates (Corning) with or without 0.1–10 µM of
S100A8, S100A9, and S100A8/A9 in the presence of 100
µg/ml polymyxin B sulfate (ICN Pharmaceuticals, Costa Mesa,
CA, USA). Culture supernatants were harvested 24 hours
later and stored at -30°C until the cytokine assay. Because the
S100 preparations contained as much as 0.722 ng of endo-
toxin, we determined whether TNF-α induction in monocytes
stimulated by 1.0 ng/ml lipopolysaccharide (LPS; Sigma, St.
Louis, MO, USA) was blocked by 100 µg/ml polymyxin B.
Monocytes were incubated at a density of 1 × 106 cells per ml
in culture medium with 10% FCS for 7 days with or without 10
ng/ml granulocyte-macrophage colony-stimulating factor
(GM-CSF) or 1 ng/ml interferon gamma (IFN-γ). The in vitro-
differentiated macrophages were stimulated for 24 hours with
2 µM S100A8/A9 in the presence of polymyxin B, and culture
supernatants were measured for TNF-α concentrations.
Preparation of endogenous secretory RAGE
Recombinant human endogenous secretory RAGE (esRAGE)
was prepared as described previously [25]. Briefly, COS-7
cells stably were transformed with pCI-neo (Promega, Madi-
son, WI, USA) carrying the esRAGE cDNA. The esRAGE pro-
tein was purified from conditioned media of the transfectant
with an AKTA purifier system using HiTrap-Heparin column,
RESOURCE S column, and HiTrap desalting column (Amer-Arthritis Research & Therapy    Vol 8 No 3    Sunahori et al.
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sham Bioscience), sequentially. The purified material largely
consisted of the 50-kDa esRAGE, as evidenced by immunore-
activity with the antibody against the peptide unique to the C
truncated-type RAGE [25].
Effects of RAGE and CD36 blockade on S100A8/A9 
stimulation
To examine the possibility of CD36 or RAGE as a putative
receptor for S100A8/A9 on monocytes, the monocyte sus-
pensions, at a density of 1 × 106 cells per ml in culture medium
with 10% FCS in 48-well plates, were stimulated for 24 hours
by 10 µM S100A8/A9 with or without 2% vol/vol goat anti-
RAGE polyclonal Ab (Chemicon International, Temecula, CA,
USA) or control goat serum (Chemicon International), 25 µg/
ml of esRAGE or human serum albumin (Sigma), and 20 µg/
ml of mouse IgG2a/κ anti-CD36 mAb (NeoMarkers, Fremont,
CA, USA) or mouse isotype-matched control mAb (NeoMark-
ers) in the presence of polymyxin B. Culture supernatants were
measured for cytokine concentrations.
Effects of MAPK inhibitors and NF-κB inhibitors on 
S100A8/A9 stimulation
To examine the involvement of MAPK and NF-κB activation in
S100A8/A9-stimulated monocyte cytokine production, mono-
cytes, at a density of 1 × 106 cells per ml in culture medium
with 10% FCS in 48-well plates, were preincubated with 1 µM
of the cell-permeable MAPK inhibitors PD98059, SB202190,
and SB203580 and the negative control SB202474 (Calbio-
chem, San Diego, CA, USA), or with or without 1 µM of the
inhibitors of NF-κB activation, 1-pyrrolidinecarbodithioic acid
(PDTC; Calbiochem), Nα-tosyl-phenylalanylchloromethylke-
tone (TPCK; Affiniti Research Products, Mamhead Castle,
UK), and BAY 11-7082 (Calbiochem) for 2 hours and were
then stimulated for 24 hours with or without 0.1–10 µM
S100A8/A9 in the presence of polymyxin B. Culture superna-
tants were measured for cytokine concentrations.
Detection of p38 MAPK activation
To detect the activation of p38 MAPK by S100A8/A9, mono-
cytes, at a density of 1 × 106 cells per ml in culture medium
with 10% FCS in 48-well plates, were stimulated for 30 min-
utes with 10 µM S100A8/A9 and were immediately placed in
the lysing buffer (Passive Lysis Buffer; Promega). The activa-
tion of p38 MAPK in cell lysates was determined using ELISA
kits for p38 MAPK protein and p38 MAPK protein phosphor-
ylated on threonine 180/tyrosine 182 (pThr180/pTyr182)
(Sigma) according to the manufacturer's instructions.
Nuclear extract and electrophoretic mobility shift assay 
for NF-κB
To examine the effects of S100A8/A9 on NF-κB activation,
monocytes, at a density of 1 × 106 cells per ml in culture
medium with 1% FCS in polypropylene tubes (Becton, Dickin-
son and Company), were stimulated with or without 0.1–10
µM S100A8/A9 in the presence of polymyxin B. Cells were
collected 30 minutes later, and nuclear proteins were pre-
pared using a nuclear extract kit (Active Motif, Carlsbad, CA,
USA) according to the manufacturer's instructions. In the
experiments of p38 MAPK inhibition, monocytes were preincu-
bated with the MAPK inhibitors (PD98059, SB202190, and
SB203580) and the control SB202474, then stimulated for
30 minutes by 10 µM S100A8/A9, and nuclear proteins were
prepared. The nuclear protein content was measured by the
Lowry method using a DC protein assay kit (Bio-Rad). Electro-
phoretic mobility shift assay (EMSA) was performed using the
Nushift NF-κB p65 kit (Active Motif) according to the manufac-
turer's instructions. Nuclear extracts were incubated with [α-
32P] dATP (Amersham, Little Chalfont, UK)-labeled double-
stranded oligonucleotide probe in binding buffer for 20 min-
utes. Samples and positive controls (nuclear proteins pre-
pared from monocytes stimulated with 100 ng/ml LPS) were
electrophoresed on 5% polyacrylamide gel, followed by auto-
radiography. To verify the specificity of NF-κB protein binding,
competition and supershift analysis was performed by adding
an excess of unlabeled competitor or mutant oligonucleotides
and rabbit polyclonal anti-NF-κB p65 Ab (Active Motif) to the
incubation on ice for 20 minutes before the binding reaction.
Statistical analysis
Samples with values below the detection limit for the assay
were regarded as negative and assigned a value of 0. Data
were expressed as the mean value ± standard error of the
Figure 1
Concentrations of S100A8 and S100A9 proteins in the serum and syn- ovial fluid (SF) of rheumatoid arthritis (RA) and osteoarthritis (OA) Concentrations of S100A8 and S100A9 proteins in the serum and syn-
ovial fluid (SF) of rheumatoid arthritis (RA) and osteoarthritis (OA). 
Paired serum and SF samples were prepared from patients with RA 
and patients with OA. Concentrations of the S100A8 and S100A9 
homodimer and the S100A8/A9 heterodimer were measured in dupli-
cate by enzyme-linked immunosorbent assay. Values are the mean ± 
standard error of the mean. n, number of samples tested.Available online http://arthritis-research.com/content/8/3/R69
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number of samples evaluated. The statistical significance of
differences between two groups was determined by the
Mann-Whitney U test or the Wilcoxon signed rank test; p val-
ues less than 0.05 were considered significant. The correla-
tion coefficient was obtained by the Spearman rank correlation
test.
Results
Increased concentrations of the S100A8/A9 heterodimer 
in serum and SF from patients with RA
Concentrations of S100A8, S100A9, and the S100A8/A9
heterodimer in paired serum and SF samples obtained from 17
patients with RA and 17 patients with OA were compared by
ELISA. The levels of S100A8, S100A9, and S100A8/A9 in
serum and SF were all significantly increased in patients with
RA (20.4 ± 7.8 ng/ml, 2.9 ± 0.3 ng/ml, and 38.9 ± 6.0 mg/ml
in serum and 65.3 ± 23.4 ng/ml, 27.9 ± 4.5 ng/ml, and 54.8
± 7.2 µg/ml in SF, respectively) as compared with patients
with OA (7.0 ± 3.0 ng/ml, 0.9 ± 0.1 ng/ml, and 16.8 ± 4.8 µg/
ml in serum and 5.1 ± 2.2 ng/ml, 3.6 ± 0.4 ng/ml, and 7.3 ±
4.5  µg/ml in SF, respectively) (Figure 1). The amounts of
S100A8/A9 heterodimers detected by ELISA were approxi-
mately 1,000-fold greater than those of S100A8 and S100A9
homodimers. S100A8/A9 was present at higher concentra-
tions in SF than in serum in patients with RA, but not in
patients with OA, and the serum levels correlated positively
with serum CRP levels in patients with RA (r = 0.802, p <
0.0001). These results suggest that S100A8 and S100A9
proteins may be secreted mainly as the heterodimer from
inflammatory cell infiltrates, such as neutrophils and mono-
cytes/macrophages, in the joints of patients with active RA;
however, these proteins are thought to be secreted also as the
homodimer, because the expression pattern of S100A8 and
S100A9 has been shown to differ in vivo, depending on cell
types, cell differentiation, and inflammatory conditions
[6,22,26].
High-level expression of S100A8/A9 by CD68+ 
macrophages in RA ST
S100A8/A9 proteins are expressed by infiltrating tissue mac-
rophages during inflammation but not by resident tissue mac-
rophages [2,3]. To determine S100A8/A9 expression at the
Figure 3
Secretion of S100A8 and S100A9 proteins from isolated synovial tis- sue (ST) cells of rheumatoid arthritis (RA) and osteoarthritis (OA) Secretion of S100A8 and S100A9 proteins from isolated synovial tis-
sue (ST) cells of rheumatoid arthritis (RA) and osteoarthritis (OA). 
Freshly isolated ST cells (1 × 106 cells per ml in culture medium with 
10% fetal calf serum) were incubated without any stimulation for 72 
hours. Culture supernatants were measured in duplicate for the 
S100A8/A9 heterodimer by enzyme-linked immunosorbent assay. Val-
ues are the mean ± standard error of the mean. n, number of samples 
tested.
Figure 2
Expression of CD68 and the S100A8/A9 heterodimer in the synovial tissue (ST) of rheumatoid arthritis (RA) Expression of CD68 and the S100A8/A9 heterodimer in the synovial tissue (ST) of rheumatoid arthritis (RA). Cryostat sections of ST samples from 
patients with RA were incubated with mouse immunoglobulin (Ig) G1 monoclonal antibody (mAb) against the S100A8/A9 complex or control mAb, 
followed by incubation with rhodamine-conjugated donkey anti-mouse IgG1 mAb, and were then incubated with fluorescein isothiocyanate-conju-
gated anti-CD68 mAb. Two-color immunofluorescence confocal images were obtained for CD68 and S100A8/A9 expression (green and red stain-
ing, respectively). The two images were superimposed; double-positive cells are shown in yellow. No isotype-matched control mAb was observed. 
Similar staining patterns were obtained in additional analyses with two synovial tissue samples from different patients.Arthritis Research & Therapy    Vol 8 No 3    Sunahori et al.
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site of macrophage infiltration, the proliferative ST samples
from three patients with RA were analyzed by two-color
immunofluorescence labeling with anti-S100A8/A9 Ab and
anti-CD68 Ab. Figure 2 shows representative staining pat-
terns of the S100A8/A9 protein and the CD68 antigen in the
ST. These tissues were characterized by the extensive infiltra-
tion of CD68-expressing macrophages. Colocalization analy-
sis revealed that the heterodimeric S100A8/A9 was highly
expressed by CD68+ macrophages, in particular the cells
localized to the lining layer. However, S100A8/A9 staining
was negligible in CD68-negative cells in the sublining layer,
including lymphocytes and vascular endothelial cells. Immu-
nostaining of the S100A8 and S100A9 homodimers shows
similar staining patterns, but the intensity and number of
S100A8 and S100A9 staining were less prominent (data not
shown). These results indicate that S100A8 and S100A9 are
expressed predominantly in the form of a heterodimeric com-
plex by highly activated macrophages in RA ST.
S100A8/A9 secretion in vitro by RA ST cells
To confirm the local production of S100A8/A9 proteins at the
site of chronic inflammation in RA, isolated cells from ST sam-
ples of nine patients with RA and six patients with OA were
incubated for 72 hours without any stimulation and culture
supernatants were measured for the heterodimer by ELISA. As
shown in Figure 3, ST cells from patients with RA spontane-
Figure 4
Induction of proinflammatory cytokine production by monocytes after  stimulation with S100A8, S100A9, and S100A8/9 Induction of proinflammatory cytokine production by monocytes after 
stimulation with S100A8, S100A9, and S100A8/9. Monocytes were 
purified by negative selection from peripheral blood mononuclear cells 
of healthy individuals. The monocyte suspensions (1 × 106 cells per ml 
in culture medium with 10% fetal calf serum) were incubated with or 
without S100A8, S100A9, and S100A8/A9 (0.1–10 µM) in the pres-
ence of polymyxin B (100 µg/ml). Culture supernatants were harvested 
24 hours later. Cytokine concentrations were measured by cytometric 
beads array (using anticytokine monoclonal antibody [mAb]-coated 
beads and phycoerythrin-conjugated anticytokine mAbs). Values are 
the mean ± standard error of the mean. IL, interleukin; n, number of 
samples tested; TNF-α, tumor necrosis factor alpha.
Figure 5
Induction of tumor necrosis factor alpha (TNF-α) production by in vitro- differentiated macrophages after S100A8/A9 stimulation Induction of tumor necrosis factor alpha (TNF-α) production by in vitro-
differentiated macrophages after S100A8/A9 stimulation. Monocytes 
(1 × 106 cells per ml in culture medium with 10% fetal calf serum) were 
incubated for 7 days with or without 10 ng/ml granulocyte-macrophage 
colony-stimulating factor (GM-CSF) or 1 ng/ml interferon gamma (IFN-
γ). The in vitro-differentiated macrophages were then stimulated for 24 
hours with 2 µM S100A8/A9 in the presence of polymyxin B (100 µg/
ml). Culture supernatants were measured for TNF-α concentrations by 
enzyme-linked immunosorbent assay. Values are the mean ± standard 
error of the mean. n, number of samples tested.Available online http://arthritis-research.com/content/8/3/R69
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ously secreted larger amounts of S100A8/A9 proteins (1.20
± 0.25 µg/ml) than did the cells from patients with OA (0.45
± 0.17 µg/ml). Lactate dehydrogenase activity in these culture
supernatants was undetectable or detectable only at negligi-
ble levels, indicating that S100A8/A9 is released as a conse-
quence of active secretion but not of cellular injury.
Although the cellular composition of ST cells was not deter-
mined in this study, we had previously measured the frequen-
cies of nonspecific esterase-staining macrophages and CD3-
positive T cells in the ST cell population isolated in the same
manner and found that RA ST samples consisted of 31.7 ±
5.3% (mean ± SD) macrophages and 44.7 ± 6.6% T cells (n
= 7) and that OA ST samples consisted of 30.3 ± 4.9% mac-
rophages and 28.8 ± 3.3% T cells (n = 4) (unpublished data).
Additionally, we could not detect significant neutrophil con-
tamination (≤1%) in two of the studied ST samples. Therefore,
it would seem that the increased S100A8/A9 secretion from
RA ST cells may be due to the presence of in vivo-activated
macrophages in the culture. This notion is likely consistent
with the fact that tissue macrophages are more activated in RA
than in OA [15,16].
Proinflammatory cytokine production by monocytes and 
in vitro-differentiated macrophages after S100A8/A9 
stimulation
Purified blood monocytes were stimulated for 24 hours by
diluted concentrations (0.1–10 µM) of recombinant S100A8
and S100A9 proteins in the presence of 100 µg/ml polymyxin
B, and culture supernatants were measured for cytokine con-
centrations by immunoassay. Polymyxin B was able to effec-
tively block TNF-α production by 1 ng/ml LPS (1,259 ± 125
pg/ml versus 36 ± 4 pg/ml; n = 3), but TNF-α production by
10 µM S100A8/A9 decreased from 1,874 ± 51 pg/ml to 955
± 40 pg/ml with polymyxin B. The results indicate that endo-
toxin contamination in the S100 proteins was not completely
neutralized by polymyxin B and that low levels of endotoxin act
in synergy with S100 proteins.
As shown in Figure 4, S100A9 and S100A8/A9 induced the
production of TNF-α, IL-1-β, IL-6, and IL-8, but not of IL-10 and
IL-12 p70, in a dose-dependent manner; all values for the com-
plex were lower than those for the A9 homodimer, although not
statistically significant. In contrast, S100A8 failed to induce
significant levels of cytokine production. It is thus likely that the
S100A9 subunit in the heterodimer is critical in activating the
proinflammatory signaling.
Next, in vitro-differentiated macrophages, prepared by incu-
bating monocytes for 7 days with or without GM-CSF or IFN-
γ, were stimulated for 24 hours by 2 µM S100A8/A9 (50 µg/
ml; equivalent to approximately the mean concentration in RA
SF), and TNF-α production was determined. As shown in Fig-
ure 5, these macrophages, particularly when treated with
cytokines, could respond well to S100A8/A9 by producing
Figure 6
Effects of mitogen-activated protein kinase (MAPK) inhibitors on  S100A8/A9-mediated cytokine production Effects of mitogen-activated protein kinase (MAPK) inhibitors on 
S100A8/A9-mediated cytokine production. Monocytes from healthy 
individuals (1 × 106 cells per ml in culture medium with 10% fetal calf 
serum) were preincubated for 2 hours in the presence of the MAPK 
inhibitors PD98059, SB202190, and SB203580 and the negative 
control SB202474 (1 µM) and were then stimulated for 24 hours with 
or without S100A8/A9 (0.1–10 µM) in the presence of polymyxin B 
(100 µg/ml). Culture supernatants were measured for cytokines by 
cytometric beads array. Values are the mean ± standard error of the 
mean. IL, interleukin; n, number of samples tested; TNF-α, tumor necro-
sis factor alpha.Arthritis Research & Therapy    Vol 8 No 3    Sunahori et al.
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TNF-α. These results suggest that the secreted S100A8/A9
heterodimer may amplify the local expression of proinflamma-
tory cytokines in joints of patients with RA.
Effects of RAGE and CD36 blockade on S100A8/A9 
stimulation
To examine whether S100A8/A9 used RAGE and CD36 as
signal transducing receptors on monocytes, monocytes were
stimulated for 24 hours by 10 µM S100A8/A9 with or without
anti-RAGE Ab, esRAGE (the splice variant lacking the trans-
membrane-spanning domain), and anti-CD36 Ab, and culture
supernatants were measured for cytokine concentrations by
immunoassay. The S100A8/A9-stimulated cytokine response
was not significantly reduced by blockade of the RAGE or
CD36 receptor (percentage of inhibition, < 30%). Therefore,
neither RAGE nor CD36 appears to be relevant to S100A8/
A9 stimulation in monocytes.
Involvement of p38 MAPK activation in S100A8/A9 
stimulation
To examine whether MAPK activation was involved in the
S100A8/A9-mediated cytokine response, monocytes were
pretreated with the MAPK inhibitors (PD98059, SB202190,
and SB203580) and the control SB202474 and were then
stimulated for 24 hours by 1–10 µM S100A8/A9. Culture
supernatants were measured for cytokine concentrations by
immunoassay. As shown in Figure 6, TNF-α, IL-1-β, and IL-6
production by S100A8/A9-stimulated monocytes was clearly
reduced by the specific p38 MAPK inhibitors SB202190 and
SB203580, while it was not affected by the MEK (mitogen-
activated/extracellular signal-regulated kinase) inhibitor
PD98059, as well as by SB202474.
To support the significance of p38 MAPK in S100A8/A9 stim-
ulation, monocytes were stimulated for 30 minutes by 10 µM
S100A8/A9, and p38 MAPK protein and phosphorylated p38
MAPK protein (pThr180/pTyr182) in cell lysates were measured
by ELISA. The phosphorylation ratio of p38 MAPK protein
(phosphorylated p38 MAPK protein/total p38 MAPK protein)
was markedly higher in S100A8/A9-stimulated monocytes
(2.17 ± 0.74 U/pg; n = 3) than in unstimulated monocytes
(0.52 ± 0.09 U/pg), proving the activation of p38 MAPK by
S100A8/A9.
Involvement of NF-κB activation in S100A8/A9 
stimulation
The transcription factor NF-κB plays a prominent role in the
activation of multiple inflammatory genes in RA [15,16]. To
determine the activation of NF-κB in S100A8/A9-stimulated
monocytes, monocytes were stimulated for 30 minutes with or
without 0.1–10 µM S100A8/A9 and nuclear proteins were
measured for the DNA-binding activity of NF-κB by EMSA. As
shown in Figure 7a, the NF-κB activity was induced by
S100A8/A9 in a dose-dependent manner, verifying the activa-
tion of NF-κB by S100A8/A9. To further determine the signif-
Figure 7
S100A8/A9-induced nuclear factor kappa B (NF-κB) activation and its  independence of p38 mitogen-activated protein kinase (MAPK) activa- tion S100A8/A9-induced nuclear factor kappa B (NF-κB) activation and its 
independence of p38 mitogen-activated protein kinase (MAPK) activa-
tion. (a) Activation of the transcriptional factor NF-κB in S100A8/A9-
stimulated monocytes. Monocytes (1 × 106 cells per ml in culture 
medium with 1% fetal calf serum) were stimulated for 30 minutes with 
or without S100A8/A9 (0.1–10 µM) in the presence of polymyxin B 
(100 µg/ml). Nuclear proteins were extracted from the cells, and elec-
tophoretic mobility shift assay (EMSA) was performed, as described in 
Materials and methods. Nuclear proteins prepared from monocytes 
stimulated with 100 ng/ml of lipopolysaccharide were used as positive 
controls. The specificity of NF-κB protein binding was verified by inhibi-
tion and supershift experiments with unlabeled NF-κB consensus or 
mutant oligonucleotides and anti-NF-κB p65 antibody. (b) Effects of 
p38 MAPK inhibition on S100A8/A9-induced NF-κB activation. Mono-
cytes, after two-hour pretreatment with or without the MAPK inhibitors 
(PD98059, SB202190, and SB203580) and the control compound 
SB202474, were stimulated for 30 minutes with or without S100A8/
A9 (10 µM), and nuclear proteins were prepared. The DNA-binding 
activity of NF-κB was determined by EMSA.Available online http://arthritis-research.com/content/8/3/R69
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icance of NF-κB activation in S100A8/A9 stimulation,
monocytes were pretreated with or without 1 µM of the NF-κB
inhibitors PDTC and TPCK and then stimulated for 24 hours
by 1 or 10 µM S100A8/A9, and culture supernatants were
measured for TNF-α concentrations. As shown in Figure 8,
TNF-α production by S100A8/A9-stimulated monocytes was
almost completely reduced by PDTC and TRCK. Similar
results were also obtained with the selective NF-κB pathway
inhibitor BAY 11-7082 (data not shown). Therefore, NF-κB
activation may be essential for the transcriptional activation of
many cytokine genes in monocytes stimulated by S100A8/A9.
To explore the interaction of p38 MAPK with NF-κB activation
in S100A8/A9 stimulation, monocytes, pretreated with or
without the MAPK inhibitors and the control compound, were
stimulated for 30 minutes by 10 µM S100A8/A9 and nuclear
proteins were measured for NF-κB activation by EMSA. As
shown in Figure 7b, MAPK inhibitors did not significantly
reduce the S100A8/A9-induced NF-κB activity, which was
verified by analysis of the images using NIH Image (National
Institutes of Health, Bethesda, MD, USA). Thus, these two sig-
naling pathways are likely to be independently involved in
cytokine production by S100A8/A9-stimulated monocytes,
and post-transcriptional and/or translational mechanisms may
be important in the p38 MAPK pathway.
Discussion
The expression of both S100A8 and S100A9, two members
of the S100 family of Ca2+-binding proteins, in infiltrating tis-
sue macrophages has been associated with chronic inflamma-
tory conditions such as RA [2]. In the present study, we found
that the S100A8/A9 heterodimer is expressed predominantly
by CD68+ macrophages in the ST of patients with RA. In addi-
tion, using the recombinant proteins, we demonstrated that
heterodimeric S100A8/A9, as well as homodimeric S100A9,
stimulates monocytes and in vitro-differentiated macrophage
to produce proinflammatory cytokines such as TNF-α.
S100A8/A9 stimulation is reduced significantly by p38 MAPK
inhibitors and NF-κB inhibitors and induces the activation of
the transcription factor NF-κB. Therefore, S100A8/A9 is con-
sidered to amplify proinflammatoy cytokine responses through
activation of NF-κB and p38 MAPK pathways in RA.
The S100A8/A9 heterodimer has been shown to be a reliable
indicator of disease activity and joint inflammation in inflamma-
tory rheumatic diseases, including RA [18,19], juvenile RA
(JRA) [27-30], psoriatic arthritis [18], and spondylarthropathy
[18]. Consistent with this finding, both serum and SF levels of
S100A8/A9 were significantly higher in patients with RA than
in patients with OA, with a positive correlation between serum
S100A8/A9 and CRP levels. S100A8 and S100A9 are inde-
pendently expressed in some pathological conditions [26], but
both proteins were increased predominantly in the form of a
heterodimeric complex in the joints of patients with active RA.
S100A8 and S100A9 molecules preferentially assemble to
noncovalently associated complexes in a Ca2+-dependent
manner [31], and heterodimers are secreted extracellularly
from neutrophils, monocytes, and tissue macrophages, but not
from lymphocytes, under inflammatory conditions [4,5,7].
The concentration of S100A8/A9 in neutrophils constitutes
up to 60% of total cytosolic protein [2], and an abundance of
S100A8/A9 complexes can be thus readily released from neu-
trophils during activation and cell death. In RA, neutrophils are
localized mainly to the SF, but not to the synovial membrane,
and act as prominent effectors of inflammation and cartilage
damage by releasing various enzymes [32]. The relationship of
S100A8/A9 levels in SF to the degree of local neutrophil infil-
tration was demonstrated in inflammatory arthritides, including
RA [18], suggesting the active secretion from infiltrating neu-
trophils. On the other hand, S100A8 and S100A9 are
secreted from monocytes as heterodimeric complexes after
activation of protein kinase, which is induced by different
inflammatory stimuli [7]. We found that S100A8/A9 was inten-
sively expressed by CD68+ macrophages in RA ST and that
isolated RA ST cells spontaneously secreted higher levels of
the protein than did OA ST cells. Taken together, these find-
ings indicate that infiltration and activation of neutrophils and
macrophages may be responsible for the elevated concentra-
tion of S100A8/A9 in joints of patients with RA.
Our immunofluorescence studies showed the distribution of
S100A8/A9-expressing macrophages in both the lining and
sublining layer of RA ST, mostly corresponding with earlier
studies of the expression pattern in the ST from RA [5,18,19],
JRA [28], and psoriatic arthritis [18]. Monocytes expressing
Figure 8
Effects of nuclear factor kappa B (NF-κB) inhibitors on S100A8/A9- mediated cytokine production Effects of nuclear factor kappa B (NF-κB) inhibitors on S100A8/A9-
mediated cytokine production. Monocytes (1 × 106 cells per ml in cul-
ture medium with 10% fetal calf serum), after two-hour pretreatment 
with or without the inhibitors of NF-κB activation (1 µM), 1-pyrrolidine-
carbodithioic acid (PDTC), and Nα-tosyl-phenylalanylchloromethylke-
tone (TPCK), were stimulated for 24 hours with or without S100A8/A9 
(1 or 10 µM) in the presence of polymyxin B. Culture supernatants 
were measured for tumor necrosis factor alpha (TNF-α) concentrations 
by enzyme-linked immunosorbent assay. Values are the mean ± stand-
ard error of the mean. n, number of samples tested.Arthritis Research & Therapy    Vol 8 No 3    Sunahori et al.
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cell surface S100A8/A9 represent a fast-migrating monocyte
subpopulation across the endothelium barrier, and high levels
of the S100A8/A9 protein are secreted after their interaction
with inflammatory-activated endothelial cells [28,33].
S100A8/A9 expression by sublining macrophages, particu-
larly by perivascular macrophages thought to represent newly
infiltrated macrophages, is attributable to selective infiltration
of S100A8/A9+ monocytes and their endothelium-dependent
induction of S100A8/A9 proteins, because the inflamed tis-
sue of RA is characterized by increased vascularity and
endothelial cell activation [34]. On the other hand, S100A8
mRNA expression in macrophages has been shown to be
stimulated by cytokines such as TNF-α, IFN-γ, and IL-10
[35,36], which are relevant to RA pathogenesis [16]. Thus,
cytokine stimulation may be responsible for S100A8/A9
expression by synovial lining macrophages (that is, the highly
activated phenotype of tissue macrophages that are capable
of producing high levels of cytokines such as TNF-α) [15]. It is
intriguing to note that there is a positive correlation between
S100A8/A9 expression and TNF-α release in alveolar macro-
phages from patients with active sarcoidosis [37].
The released S100A8/A9 heterodimer may play a role in the
propagation of inflammation by recruiting neutrophils and
monocytes to joints of patients with RA. Extracellular S100A8/
A9 enhances the transendothelial migration of these inflamma-
tory cells by enhancing CD11b expression and affinity for
intracellular adhesion molecule-1 (ICAM-1) [33,38]. We found
that S100A8/A9 stimulated monocytes and in vitro-differenti-
ated macrophages to produce proinflammatory cytokines
such as TNF-α. In addition, co-stimulation of S100A8/A9 with
LPS and cytokines such as TNF-α, IL-1-β, and IFN-γ showed
synergistic effects on monocyte cytokine production (data not
shown). However, S100A8/A9 was less effective in terms of
monocyte stimulation compared with cytokines; the protein of
10-7 to 10-5 M concentrations (2.4–240 µg/ml) was required
for significant cytokine induction, whereas cytokines are
known to produce their actions in the range of 10-12 to 10-9 M
concentrations [39]. Despite its lower efficacy, S100A8/A9
stimulation is believed to be effective in joints of patients with
RA, where the protein is present at 54.8 ± 28.6 µg/ml,
because in vitro-differentiated macrophages, as well as freshly
isolated monocytes (data not shown), when stimulated with 2
µM (50 µg/ml) S100A8/A9, could produce significant levels
of TNF-α. Similarly, 15 µg/ml S100A8/A9 significantly
induced IL-8 release from bronchial epithelial cells, and anti-
S100A8/A9 Ab treatment reduced the IL-8-stimulating poten-
tial of bronchial secretions [40]. More recently, the study using
microarray analysis demonstrated that S100A8/A9 proteins
(100 µg/ml) directly activate endothelial cells to induce proin-
flammatory chemokines and adhesion molecules and to
increase vascular permeability [41]. Taken together, these
findings suggest the significance of S100A8/A9 as key effec-
tors/amplifiers of inflammation with a wide range of activities,
including cytokine induction.
Considering the potential inflammatory properties, there
seems to be a discrepancy between high concentrations of
serum S100A8/A9 and the lack of its peripheral effect in
patients with RA. We speculate that the yet-unidentified, inhib-
itory molecules for S100A8/A9 activity might be present in the
blood circulation, as is well recognized in the regulation of
TNF-α and IL-1 activities by soluble TNF receptors and IL-1
receptor antagonist which bind to the protein or interfering
with its cell interaction, respectively [15,16]. However, it is
also conceivable that an abundance of the protein might par-
tially contribute to monocyte activation before entry into the
joint, as evidenced by the increase of circulating CD16+
mature monocytes in patients with RA [42].
The S100A9 homodimer, but not the S100A8 homodimer,
stimulated the monocyte/macrophage cytokine response.
Similarly, the S100A9 homodimer, as well as the S100A8/A9
complex, could enhance ICAM-1 binding to monocytes,
whereas the S100A8 homodimer failed to do so [33]. The
S100A9 subunit is thus likely to be critical in eliciting the
inflammatory signaling pathway. Interestingly, values of
cytokine production with S100A8/A9 tend to be lower than
those with S100A9, which may indicate partial inhibition of
S100A9 stimulation by its heterodimeric partner S100A8.
However, we could not clearly detect inhibitory effects of
S100A8 on S100A9-induced TNF-α production when titrat-
ing S100A8 concentrations (0.1–10 µM) into the 1 µM
S100A9 solution (data not shown), although the possibility
still remains that much higher concentrations of S100A8 are
required for its significant inhibition. The S100A9 protein stim-
ulates the β2  integrin (CD11/CD18)-mediated neutrophil
adhesion by inducing the high-affinity CD11b epitope, and this
S100A9 activity is specifically inhibited by S100A8 [38]. More
importantly, recent studies have demonstrated that numbers
of S100A8/A9-expressing macrophages increased in the ST
of patients with RA after treatment with high dose of intrave-
nous methylprednisolone and that high levels of S100A8
induced by glucocorticoids have anti-inflammatory properties
independent of hetero-complex formation with S100A9 [43].
These findings support the possible inhibition of the het-
erodimer-induced cytokine response by the S100A8 subunit.
RAGE, originally defined by its binding to advanced glycation
endproducts, has been identified as a multiligand receptor that
can bind inflammatory molecules such as HMGB1 (high mobil-
ity group box chromosomal protein 1), S100A12, and
S100B1 [14,44]. Significant similarities in structure among
S100A8, S100A9, and S100A12 suggest that RAGE may
function as a signal-transducing receptor for these S100 pro-
teins. In addition, the CD36 molecule, a member of the scav-
enger receptor family, has been shown to bind the complex of
S100A8/A9 and AA and induce uptake of exogenous AA into
the endothelial cells [13]. However, S100A8/A9-mediated
cytokine production was not inhibited by anti-RAGE Ab,
esRAGE (an endogenous inhibitor of RAGE activity), or anti-Available online http://arthritis-research.com/content/8/3/R69
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CD36, excluding the possibility of RAGE or CD36 as a puta-
tive receptor for S100A8/A9. Thus, S100A8/A9 may induce
cell activation after its nonspecific interaction with monocytes,
because S100A8/A9 binds endothelial cells in conjunction
with heparin sulfate proteoglycans and novel carboxylated gly-
cans [11,12].
The significance of NF-κB and MAPK pathways in the inflam-
matory gene activation in joints of patients with RA has been
well established [15,16]. We found that S100A8/A9, like
TNF-α and IL-1, efficiently activate both the NF-κB and p38
MAPK pathways, resulting in cytokine production in mono-
cytes.
Because MAPK inhibitors did not reduce the DNA-binding
activity of NF-κB, these two critical signaling pathways may be
independently involved in S100A8/A9-mediated cytokine pro-
duction. NF-κB inhibitors could completely block the cytokine
response. Therefore, we believe that the transcriptional activity
of NF-κB may be most critical in S100A8/A9-induced
cytokine expression in monocytes/macrophages and that p38
MAPK may regulate the synthesis of cytokines at the post-tran-
scriptional and/or translational levels
Conclusion
In summary, the S100A8/A9 heterodimer, highly expressed by
synovial lining macrophage, may play a role in amplifying proin-
flammatory cytokine responses via activation of NF-κB and
p38 MAPK in RA.
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